Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has become a milestone in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) in the last decade. Contemporary data suggest that sacubitril/valsartan is associated with i...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2021-04-01
|
| Series: | Cardiac Failure Review |
| Online Access: | https://www.cfrjournal.com/articleindex/cfr.2020.25 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846122506381950976 |
|---|---|
| author | Mauro Gori James L Januzzi Emilia D’Elia Ferdinando L Lorini Michele Senni |
| author_facet | Mauro Gori James L Januzzi Emilia D’Elia Ferdinando L Lorini Michele Senni |
| author_sort | Mauro Gori |
| collection | DOAJ |
| description | Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has become a milestone in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) in the last decade. Contemporary data suggest that sacubitril/valsartan is associated with improved outcomes compared with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and has a greater beneficial effect on myocardial reverse remodelling. Additionally, two recent trials have shown that sacubitril/valsartan is well-tolerated even in the acute HF setting, thus enabling a continuum of use in the patient’s journey with HFrEF. This article summarises available data on the effectiveness and tolerability of sacubitril/valsartan in patients with HFrEF, and provides the clinician with practical insights to facilitate the use of this drug in every setting, with an emphasis on acute HF, hypotension, electrolyte imbalance and renal insufficiency. |
| format | Article |
| id | doaj-art-f312d9e2247a4d8ab1a5ab02466600bc |
| institution | Kabale University |
| issn | 2057-7540 2057-7559 |
| language | English |
| publishDate | 2021-04-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | Cardiac Failure Review |
| spelling | doaj-art-f312d9e2247a4d8ab1a5ab02466600bc2024-12-14T16:02:39ZengRadcliffe Medical MediaCardiac Failure Review2057-75402057-75592021-04-01710.15420/cfr.2020.25Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection FractionMauro Gori0James L Januzzi1Emilia D’Elia2Ferdinando L Lorini3Michele Senni4Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, ItalyCardiology Division, Massachusetts General Hospital, Boston, MA, USCardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, ItalyIntensive Care Department, Papa Giovanni XXIII Hospital, Bergamo, ItalyCardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, ItalySacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has become a milestone in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) in the last decade. Contemporary data suggest that sacubitril/valsartan is associated with improved outcomes compared with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and has a greater beneficial effect on myocardial reverse remodelling. Additionally, two recent trials have shown that sacubitril/valsartan is well-tolerated even in the acute HF setting, thus enabling a continuum of use in the patient’s journey with HFrEF. This article summarises available data on the effectiveness and tolerability of sacubitril/valsartan in patients with HFrEF, and provides the clinician with practical insights to facilitate the use of this drug in every setting, with an emphasis on acute HF, hypotension, electrolyte imbalance and renal insufficiency.https://www.cfrjournal.com/articleindex/cfr.2020.25 |
| spellingShingle | Mauro Gori James L Januzzi Emilia D’Elia Ferdinando L Lorini Michele Senni Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction Cardiac Failure Review |
| title | Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction |
| title_full | Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction |
| title_fullStr | Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction |
| title_full_unstemmed | Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction |
| title_short | Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction |
| title_sort | rationale for and practical use of sacubitril valsartan in the patient s journey with heart failure and reduced ejection fraction |
| url | https://www.cfrjournal.com/articleindex/cfr.2020.25 |
| work_keys_str_mv | AT maurogori rationaleforandpracticaluseofsacubitrilvalsartaninthepatientsjourneywithheartfailureandreducedejectionfraction AT jamesljanuzzi rationaleforandpracticaluseofsacubitrilvalsartaninthepatientsjourneywithheartfailureandreducedejectionfraction AT emiliadelia rationaleforandpracticaluseofsacubitrilvalsartaninthepatientsjourneywithheartfailureandreducedejectionfraction AT ferdinandollorini rationaleforandpracticaluseofsacubitrilvalsartaninthepatientsjourneywithheartfailureandreducedejectionfraction AT michelesenni rationaleforandpracticaluseofsacubitrilvalsartaninthepatientsjourneywithheartfailureandreducedejectionfraction |